Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

This study has been terminated.
(Slow accrual)
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
Information provided by (Responsible Party):
Rutgers, The State University of New Jersey Identifier:
First received: February 27, 2009
Last updated: February 13, 2017
Last verified: May 2015

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Infusing irradiated donor lymphocytes into the patient may help the patient's immune system kill tumor cells. Giving sunitinib together with irradiated donor lymphocytes may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving sunitinib together with irradiated donor lymphocytes works in treating patients with metastatic kidney cancer.

Condition Intervention Phase
Kidney Cancer
Biological: therapeutic allogeneic lymphocytes
Drug: sunitinib malate
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)

Resource links provided by NLM:

Further study details as provided by Rutgers, The State University of New Jersey:

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: Treatment start date to date of progression ]

Secondary Outcome Measures:
  • Rates and kinetics of clinical/radiographic response [ Time Frame: Treatment start date to best response ]
  • Toxicity as assessed by NCI CTCAE v3.0 [ Time Frame: Treatment start date to off study ]
  • Stable disease at 6 months [ Time Frame: Treatment start date to 6 months ]
  • Overall survival [ Time Frame: Treatment start date to date of death ]

Enrollment: 10
Study Start Date: February 2009
Study Completion Date: February 22, 2014
Primary Completion Date: February 22, 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sunitinib plus Irradiated Allogeneic Lymphocytes Biological: therapeutic allogeneic lymphocytes
Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
Drug: sunitinib malate
Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.

Detailed Description:



  • Determine progression-free survival of patients with metastatic clear cell renal cell carcinoma treated with sunitinib and irradiated allogeneic lymphocytes.


  • Determine rates and kinetics of clinical/radiographic response in these patients.
  • Determine toxicities associated with treatment in these patients.
  • Assess stable disease at 6 months in these patients.
  • Assess overall survival of these patients.

OUTLINE: Patients receive oral sunitinib malate once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Beginning with course 2 of sunitinib malate, patients also receive irradiated allogeneic lymphocytes IV over 1 hour every 8-16 weeks for up to 6 infusions in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 60 days.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed renal cell carcinoma

    • Primary lesion or metastatic site demonstrating clear cell variant with < 25% of any other histology
  • Radiographically measurable disease by RECIST criteria
  • Initiated treatment with sunitinib malate ≤ 6 weeks ago
  • No radiographically detectable brain metastases by MRI or CT scan
  • HLA-partially matched related donor available, as determined by serologic and/or DNA typing

    • Appropriate HLA match (≥ 2/6 HLA A, B, DR match)


  • ECOG performance status 0-1
  • Absolute neutrophil count > 1,500/mm³
  • Platelet count > 100,000/mm³
  • Total bilirubin ≤ 2.0 times upper limit of normal (ULN)
  • AST ≤ 3.0 times ULN
  • Calculated creatinine clearance ≥ 40 mL/min
  • Cardiac ejection fraction ≥ 50%
  • QTc interval < 500 msec by EKG
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No known HIV positivity
  • None of the following within the past 6 months:

    • Myocardial infarction
    • Severe/unstable angina
    • Coronary/peripheral artery bypass graft
    • Symptomatic congestive heart failure
    • Cerebrovascular accident or transient ischemic attack
    • Pulmonary embolism
  • No ongoing ventricular cardiac dysrhythmias ≥ grade 2, according to NCI CTCAE v3.0
  • No history of serious ventricular arrhythmia (e.g., ventricular tachycardia > 3 beats in a row)
  • No ongoing atrial fibrillation
  • No other malignancies within the past 3 years, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ of the breast
  • No other concurrent serious illness


  • See Disease Characteristics
  • No prior systemic therapy for metastatic renal cell carcinoma
  • No prior immunotherapy
  • No prior VEGF-targeted or mTOR-targeted therapies
  • No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), St. John's wort, ketoconazole, dexamethasone, dysrhythmic drugs (e.g., terfenadine, quinidine, procainamide, sotalol, probucol, bepridil, indapamide, or flecainide), haloperidol, risperidone, rifampin, grapefruit, or grapefruit juice
  • No other concurrent investigational anticancer agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00853125

United States, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903
Sponsors and Collaborators
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
Principal Investigator: Roger Strair, MD, PhD Rutgers Cancer Institute of New Jersey
  More Information

Responsible Party: Rutgers, The State University of New Jersey Identifier: NCT00853125     History of Changes
Other Study ID Numbers: 080708
P30CA072720 ( US NIH Grant/Contract Award Number )
CDR0000635763 ( Other Identifier: NCI )
0220080220 ( Other Identifier: IRB )
Study First Received: February 27, 2009
Last Updated: February 13, 2017

Keywords provided by Rutgers, The State University of New Jersey:
clear cell renal cell carcinoma
stage IV renal cell cancer

Additional relevant MeSH terms:
Kidney Neoplasms
Carcinoma, Renal Cell
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on May 25, 2017